September 11th 2020EP. 1: Pathophysiology of Different Types of Heart Failure
September 11th 2020EP. 2: Progressive Nature and Associated Risks of Diabetes on HF
September 11th 2020EP. 3: Cost and Utilization Profile for a Patient With HF
September 11th 2020EP. 4: Economic Burden of Heart Failure and Goals of Treatment
September 11th 2020EP. 5: Standard of Care in Patients With Heart Failure
September 11th 2020EP. 6: Reducing Readmissions Due to Heart Failure
September 11th 2020EP. 7: CV Outcomes Studies With Medications Indicated for Diabetes
September 11th 2020EP. 8: Recent Studies of SGLT-2s in Patients with HFrEF
September 11th 2020EP. 9: Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF
September 11th 2020EP. 10: SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF
September 11th 2020EP. 11: SGLT2 Inhibitors as Standard of Care Throughout Cardiology
September 11th 2020EP. 12: Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF
September 11th 2020EP. 13: Quantifying Potential Impact of SGLT2 Inhibitors for HF
September 11th 2020EP. 14: Systemic Change to Support Care of Patients With HF
September 11th 2020EP. 15: Treatment of Patients With Heart Failure
September 11th 2020EP. 16: Interest Regarding Diabetes and CVD Risk
September 11th 2020EP. 17: Takeaways of DAPA-HF: SGLT2s for CVD
September 11th 2020EP. 18: Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits
September 11th 2020EP. 19: Cost-Effectiveness of SGLT2s for CVD
